RxDoctor Payments Data

Scott Stevens, OD

Optometrist · Venice, FLNPI 1275644486

Payments from drug & device makers

$1,309in general payments, 2019–2025

Across 22 payments — averaging $59.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$244
  • Alcon$170
  • Johnson & Johnson Vision Care, Inc.$147
  • Bausch & Lomb Americas Inc.$142
  • Rxsight Inc$130
  • Dompe US, Inc.$123
  • plus $353 from 7 others

What the payments were for

  • Food & beverage$1,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,309 in reported general payments places this provider in the 55th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$299,217
Medicare patients
1,937
Services billed
3,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine34$34,393
LumiganBimatoprost28$16,189
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol43$6,580
RocklatanNetarsudil Mesylat/Latanoprost12$6,552
CombiganBrimonidine Tartrate/Timolol15$4,451
Latanoprost281$2,928
Fluorometholone20$2,683
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha276$2,635
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat101$1,413
Brimonidine Tartrate83$1,411
Prednisolone Acetate27$1,235
Timolol Maleate90$1,096
MoxifloxacinMoxifloxacin Hcl40$680
Dorzolamide Hcl32$620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$28$55,03377 claims
Aerie Pharmaceuticals, Inc.Rocklatan$19$6,55212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →